Drug · CHEMBL658
SUFENTANIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. SUFENTANIL. Drugs and targets, record CHEMBL658. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL658
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 2 of its 27 diseases, from EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | Mu opioid receptor agonist | AGONIST | https://conductscience.org/library/genes/4988 |
Source ChEMBL
Diseases27
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| Pain | Approval | EMA Human Drugs | 17 | 15 | https://conductscience.org/library/drugs?q=HP_0012531 |
| Hypoxemia | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0012418 |
| hypotensive disorder | Unknown | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005468 |
| Chronic pain | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012532 |
| Cough | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012735 |
| Dyskinesia | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0100660 |
| Loss of consciousness | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0007185 |
| Paresthesia | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0003401 |
| Pruritus | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0000989 |
| Strabismus | Unknown | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0000486 |
1 to 10 of 27Source Open Targets
See all 27 diseasesTrials219
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02625181 | Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis | 27,034 | 2019-03-07 | sufentanil | Its name | ClinicalTrials.gov | |
| NCT03726268 | Optimizing Outpatient Anesthesia (OSPREy-Outpatient Surgery Pain Relief Enhancement) | Phase 4 | 907 | 2025-11-19 | sufentanil | Its name | ClinicalTrials.gov |
| NCT01660763 | Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery | Phase 3 | 419 | 2014-02-03 | sufentanil | Its name | ClinicalTrials.gov |
| NCT01539538 | A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™)to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain | Phase 3 | 357 | 2014-03-27 | sufentanil | Its name | ClinicalTrials.gov |
| NCT02662764 | Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg | Phase 3 | 320 | 2018-08-08 | sufentanil | Its name | ClinicalTrials.gov |
| NCT04263909 | The Impact of Sublingual Sufentanil on Postoperative Pain and Analgesic Requirements in Spine Surgery Patients | Phase 4 | 199 | 2025-03-30 | sufentanil | Its name | ClinicalTrials.gov |
| NCT01490580 | Premedication Trial for Tracheal Intubation of the NEOnate | Phase 2/3 | 173 | 2019-09-13 | sufentanil | Its name | ClinicalTrials.gov |
| NCT01539642 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Open Abdominal Surgery | Phase 3 | 172 | 2014-02-03 | sufentanil | Its name | ClinicalTrials.gov |
| NCT02356588 | A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery | Phase 3 | 161 | 2017-02-13 | sufentanil | Its name | ClinicalTrials.gov |
| NCT06364072 | Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients | Phase 2/3 | 155 | 2026-02-02 | sufentanil | Its name | ClinicalTrials.gov |
1 to 10 of 219
See all 219 trialsComparisons in its trials46
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sufentanil NanoTab PCA System/15 mcg vs Placebo Sufentanil NanoTab PCA System: serious adverse events | 8 of 315 | 4 of 104 | 419 | NCT01660763 | Trial comparisons |
| Sufentanil NanoTab PCA System/15 mcg vs Morphine IV PCA: serious adverse events | 6 of 177 | 7 of 180 | 357 | NCT01539538 | Trial comparisons |
| Sufentanil NanoTab PCA System/15 mcg vs Placebo Sufentanil NanoTab PCA System: serious adverse events | 1 of 114 | 0 of 58 | 172 | NCT01539642 | Trial comparisons |
| Atropine Atracurium Sufentanil vs Atropine Propofol: Number of Patients With Prolonged Desaturation | 54 of 82 | 53 of 89 | 171 | NCT01490580 | Trial comparisons |
| Atropine Atracurium Sufentanil as Treated Population vs Atropine Propofol as Treated Population: Number of Patients Surviving Without Ages and Stages Questionnaire Score Below Threshold at Age 2 | 38 of 81 | 45 of 85 | 166 | NCT01490580 | Trial comparisons |
| Atropine + Propofol vs Atropine + Atracurium + Sufentanil: deaths from any cause | 2 of 83 | 3 of 80 | 163 | NCT01490580 | Trial comparisons |
| Atropine + Propofol vs Atropine + Atracurium + Sufentanil: serious adverse events | 9 of 83 | 16 of 80 | 163 | NCT01490580 | Trial comparisons |
| Sufentanil Tablet 30 mcg vs Placebo Tablet: serious adverse events | 0 of 107 | 2 of 54 | 161 | NCT02356588 | Trial comparisons |
| DSUVIA (Sufentanil) vs Standard Care: Number of Participants With Vomiting | 3 of 76 | 0 of 74 | 150 | NCT05288348 | Trial comparisons |
| DSUVIA (Sufentanil) vs Standard Care: Number of Participants With Nausea | 5 of 76 | 3 of 74 | 150 | NCT05288348 | Trial comparisons |
1 to 10 of 46
See all 46 comparisons in its trialsPapers from its trials94
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Contour Integration Task | 1 | 0 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL658
GET https://conductscience.org/api/drugs/v1/CHEMBL658/diseases?page=2